Literature DB >> 17310329

Social outcome in adults with maple syrup urine disease (MSUD).

E Simon1, M Schwarz, U Wendel.   

Abstract

BACKGROUND: In MSUD, dietary treatment aims at the protection of the brain from functional disturbances and structural damage by keeping the branched-chain amino acids in plasma permanently in the near-normal range. Unfortunately, delay in effective treatment of the neonatal manifestation and poor long-term metabolic control are common in MSUD patients, leading to impaired cognitive outcome. Some studies have analysed cognitive capacity but only few data are available on social status (educational qualification, interpersonal relationships, lifestyle) in adult patients, which is one measure for the success of treatment. AIM: In this study we analysed sociodemographic data of 22 adult patients suffering from classic or very severe variant MSUD in comparison with data on an age-matched control collective of the population of Germany.
RESULTS: The analysis revealed low educational and professional levels with a low rate of participation in the labour force by adult MSUD patients. The educational level in patients of migrant origin was lower than the educational qualifications in the native patient group. A large number of patients did not live a normal adult life. Patients could not live autonomously, did not have a steady partnership and had no children.
CONCLUSION: Despite substantial improvement in the treatment of MSUD in recent years, unimpaired outcome of patients with classic or very severe variant MSUD remains a rare finding. Care must be further optimized in order to improve intellectual and, thereby, social outcome. Particular care must be exercised in the treatment of migrant patients who offer special problems due to cultural peculiarities and language difficulties.

Entities:  

Mesh:

Year:  2007        PMID: 17310329     DOI: 10.1007/s10545-007-0475-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

1.  Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience.

Authors:  George V Mazariegos; D Holmes Morton; Rakesh Sindhi; Kyle Soltys; Navdeep Nayyar; Geoffrey Bond; Diana Shellmer; Benjamin Shneider; Jerry Vockley; Kevin A Strauss
Journal:  J Pediatr       Date:  2011-08-11       Impact factor: 4.406

2.  Developmental Defects of Caenorhabditis elegans Lacking Branched-chain α-Ketoacid Dehydrogenase Are Mainly Caused by Monomethyl Branched-chain Fatty Acid Deficiency.

Authors:  Fan Jia; Mingxue Cui; Minh T Than; Min Han
Journal:  J Biol Chem       Date:  2015-12-18       Impact factor: 5.157

3.  Phenylbutyrate therapy for maple syrup urine disease.

Authors:  Nicola Brunetti-Pierri; Brendan Lanpher; Ayelet Erez; Elitsa A Ananieva; Mohammad Islam; Juan C Marini; Qin Sun; Chunli Yu; Madhuri Hegde; Jun Li; R Max Wynn; David T Chuang; Susan Hutson; Brendan Lee
Journal:  Hum Mol Genet       Date:  2010-11-23       Impact factor: 6.150

4.  Docosahexaenoic acid status in females of reproductive age with maple syrup urine disease.

Authors:  Laura M Mazer; Sarah H L Yi; Rani H Singh
Journal:  J Inherit Metab Dis       Date:  2010-03-09       Impact factor: 4.982

5.  Communication of genetic information by other health professionals: the role of the genetic counsellor in specialist clinics.

Authors:  Rosie O'Shea; Anne Marie Murphy; Eileen Treacy; Sally Ann Lynch; Kathryn Thirlaway; Debby Lambert
Journal:  J Genet Couns       Date:  2011-01-06       Impact factor: 2.537

6.  Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuk; Gustavo C Ferreira; Joao Seda Neto; Tatiana Amorin; Ida Vanessa D Schwartz; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 7.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

8.  Structural white matter changes in adolescents and young adults with maple syrup urine disease.

Authors:  D Klee; E Thimm; H J Wittsack; D Schubert; R Primke; G Pentang; J Schaper; U Mödder; A Antoch; U Wendel; M Cohnen
Journal:  J Inherit Metab Dis       Date:  2013-01-25       Impact factor: 4.982

9.  Classical maple syrup urine disease and brain development: principles of management and formula design.

Authors:  Kevin A Strauss; Bridget Wardley; Donna Robinson; Christine Hendrickson; Nicholas L Rider; Erik G Puffenberger; Diana Shellmer; Diana Shelmer; Ann B Moser; D Holmes Morton
Journal:  Mol Genet Metab       Date:  2010-01-12       Impact factor: 4.797

10.  Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease.

Authors:  William J Zinnanti; Jelena Lazovic; Kathleen Griffin; Kristen J Skvorak; Harbhajan S Paul; Gregg E Homanics; Maria C Bewley; Keith C Cheng; Kathryn F Lanoue; John M Flanagan
Journal:  Brain       Date:  2009-03-17       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.